Table 3 PsA resistance risk factors for clinical outcomes
From: Real-world use of ceftolozane/tazobactam: a systematic literature review
Citation, study design, location | N C/T | Patient/infection description | Analysis | Variable | Proportion of patients with either outcome with variable | p-value | |
|---|---|---|---|---|---|---|---|
Rodriguez-Nunez et al. 2019 [28] Retrospective, multicenter International | 90 | Drug-resistant PsA RTIs (76.7% XDR; 23.3% MDR) | Univariate regression | XDR PsA infection | Survivors (N = 65) | Non-survivors (N = 25) | .308 |
73.8% (48/65) | 84.0% (21/25) | ||||||
Diaz-Cañestro et al. 2018 [30] Prospective, single center Spain | 58 | PsA (86.2% XDR; 10.3% MDR) infections, including RTIs (60.3%), UTIs (17.2%), and IAIs (6.9%) | Univariate regression |  | Clinical cure (N = 35) | Clinical failure (N = 21) |  |
Resistance profile | Â | Â | .045 | ||||
XDR PsA infection | 82.8% (29/35) | 100.0% (21/21) | |||||
MDR PsA infection | 17.1% (6/35) | 0.0% (0/21) | |||||